RecruitingCardiovascular EventsMACE
Tezspire Cardiac Events PASS
Eligible age
12–130 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for severe asthma.
Sponsor: AstraZeneca
You may qualify if…
- ✓ patients with a diagnosis of asthma receiving tezepelumab or high-intensity SOC treatment for severe asthma at any point during the study inclusion period.
You may not qualify if…
- ✕ \<12 months of data availability prior to index date,
- ✕ age \<12 years at index date,
- ✕ history of congenital heart disease or heart transplant outcome-specific exclusion criterion applied for each objective will include the presence of non-fatal myocardial infarction or stroke and the specific outcome of interest in the 180 days prior to index date
- ✕ for comparative analysis, an additional exclusion criterion will be considered, i.e. exposure to non-tezepelumab biologics on index date or within the 5-half-life clearance period of the biologic
- ✕ matching criteria (including, among other variables, the type and duration of SOC exposure in the 12 months before index date and propensity score \[PS\] matching) will be applied to ensure exposed and unexposed patients' comparability
Where it's recruiting
Delaware
Wilmington
Source: ClinicalTrials.gov · NCT06951867 · last updated 2026-06-04